2 assets in Nasal Cavity And Paranasal Sinus Carcinoma

Therapeutic assets addressing Nasal Cavity And Paranasal Sinus Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Nasal Cavity And Paranasal Sinus Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Valemetostat Nasal Cavity And Paranasal Sinus Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)